Stammdaten
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Unternehmen & Branche
| Name | PetVivo Holdings, Inc. |
|---|---|
| Ticker | PETV |
| CIK | 0001512922 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 21,7 Mio. USD |
| Beta | 1,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 286,108 | -2,191,455 | -0.07 | 4,376,154 | 3,378,750 |
| 2025-09-30 | 10-Q | 303,284 | -3,007,809 | -0.11 | 5,258,269 | 4,182,972 |
| 2025-06-30 | 10-Q | 297,500 | -2,311,037 | -0.09 | 6,890,496 | 3,730,977 |
| 2025-03-31 | 10-K | 1,132,533 | -8,399,166 | -0.41 | 9,339,195 | 4,219,248 |
| 2024-12-31 | 10-Q | 583,313 | -1,757,038 | -0.09 | 3,112,340 | -694,781 |
| 2024-09-30 | 10-Q | 200,720 | -2,175,493 | -0.11 | 3,186,744 | 409,171 |
| 2024-06-30 | 10-Q | 123,751 | -2,047,063 | -0.11 | 2,888,930 | 829,503 |
| 2024-03-31 | 10-K | 968,706 | -10,955,295 | -0.78 | 3,115,253 | 685,953 |
| 2023-12-31 | 10-Q | 595,891 | -1,749,848 | -0.12 | 3,629,802 | 895,100 |
| 2023-09-30 | 10-Q | 207,366 | -3,661,153 | -0.28 | 4,061,737 | 988,679 |
| 2023-06-30 | 10-Q | 117,183 | -2,893,577 | -0.25 | 3,099,197 | 398,239 |
| 2023-03-31 | 10-K | 917,162 | -8,717,608 | -0.85 | 2,438,952 | 725,025 |
| 2022-12-31 | 10-Q | 510,109 | -2,311,618 | -0.23 | 2,568,295 | 784,150 |
| 2022-09-30 | 10-Q | 223,280 | -2,111,589 | -0.21 | 4,050,809 | 2,563,385 |
| 2022-06-30 | 10-Q | 58,174 | -1,965,428 | -0.20 | 5,723,557 | 4,252,525 |
| 2022-03-31 | 10-K | 115,586 | -5,014,995 | 7,427,332 | 5,986,722 | |
| 2021-12-31 | 10-Q | 51,004 | -1,642,129 | 8,496,109 | 7,249,922 | |
| 2021-09-30 | 10-Q | 4,977 | -1,105,474 | 9,914,124 | 8,548,254 | |
| 2021-06-30 | 10-Q | 4,145 | -490,629 | -716,178 | ||
| 2021-03-31 | 10-K | 12,578 | -3,522,780 | 835,247 | -896,979 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-23 | A.L. Sarroff Fund, LLC | 10% Owner | Open Market Purchase | 1,000 | 0.75 | 749.90 | +13,7% | |
| 2026-03-23 | A.L. Sarroff Fund, LLC | 10% Owner | Open Market Purchase | 23,033 | 0.68 | 15,662.44 | +286,3% | |
| 2026-03-13 | A.L. Sarroff Fund, LLC | 10% Owner | Open Market Purchase | 1,250,000 | 0.00 | 0.00 | 0,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.